Measuring the Impact of Targeting FcRn-Mediated IgG Recycling on Donor-Specific Alloantibodies in a Sensitized NHP Model.
Journal Article (Journal Article)
BACKGROUND: In transplantation, plasmapheresis and IVIg provide the mainstay of treatment directed at reducing or removing circulating donor-specific antibody (DSA), yet both have limitations. We sought to test the efficacy of targeting the IgG recycling mechanism of the neonatal Fc receptor (FcRn) using anti-FcRn mAb therapy in a sensitized non-human primate (NHP) model, as a pharmacological means of lowering DSA. METHODS: Six (6) rhesus macaque monkeys, previously sensitized by skin transplantation, received a single dose of 30mg/kg anti-RhFcRn IV, and effects on total IgG, as well as DSA IgG, were measured, in addition to IgM and protective immunity. Subsequently, 60mg/kg IV was given in the setting of kidney transplantation from skin graft donors. Kidney transplant recipients received RhATG, and tacrolimus, MMF, and steroid for maintenance immunosuppression. RESULTS: Circulating total IgG was reduced from a baseline 100% on D0 to 32.0% (mean, SD ± 10.6) on d4 post infusion (p<0.05), while using a DSA assay. T-cell flow cross match (TFXM) was reduced to 40.6±12.5% of baseline, and B-cell FXCM to 52.2±19.3%. Circulating total IgM and DSA IgM were unaffected by treatment. Pathogen-specific antibodies (anti-gB and anti-tetanus toxin IgG) were significantly reduced for 14d post infusion. Post-transplant, circulating IgG responded to anti-FcRn mAb treatment, but DSA increased rapidly. CONCLUSION: Targeting the FcRn-mediated recycling of IgG is an effective means of lowering circulating donor-specific IgG in the sensitized recipient, although in the setting of organ transplantation mechanisms of rapid antibody rise post-transplant remains unaffected.
Full Text
Duke Authors
Cited Authors
- Manook, M; Flores, WJ; Schmitz, R; Fitch, Z; Yoon, J; Bae, Y; Shaw, B; Kirk, A; Harnois, M; Permar, S; Farris, AB; Magnani, DM; Kwun, J; Knechtle, S
Published Date
- 2021
Published In
Volume / Issue
- 12 /
Start / End Page
- 660900 -
PubMed ID
- 34149698
Pubmed Central ID
- PMC8207189
Electronic International Standard Serial Number (EISSN)
- 1664-3224
Digital Object Identifier (DOI)
- 10.3389/fimmu.2021.660900
Language
- eng
Conference Location
- Switzerland